Atara Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atara Biotherapeutics, Inc. on November 26, 2021. The report discloses the execution of a new sales agreement to facilitate the potential sale of common stock.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial metric disclosed is the authorization of an "at-the-market" (ATM) offering facility with an aggregate offering price of up to $100.0 million.
Material Changes
On November 26, 2021, the Company entered into a Sales Agreement (the "2021 ATM Facility") with Cowen and Company, LLC. Under this agreement, the Company may offer and sell shares of its common stock through Cowen as a sales agent. The Company is not obligated to make any sales under this facility.
Guidance, Outlook, and Terms
- Sales Agent: Cowen and Company, LLC.
- Commission: The Company will pay Cowen a commission of up to 3.0% of the gross sales proceeds.
- Method: Sales may be made directly on the Nasdaq Global Select Market or other trading markets deemed "at the market offerings" under Rule 415.
- Termination: The facility terminates upon the sale of all subject stock or earlier termination in accordance with its terms.
- Registration: Shares will be offered pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-253731).
Investor Verification Checklist
- Verify the status of the prospectus supplement to be filed with the SEC regarding the ATM Offering.
- Monitor future 8-K filings or quarterly reports for actual sales volumes and proceeds generated under the $100.0 million facility.
- Review the Company's cash position in subsequent filings to assess the necessity of utilizing this facility.
- Confirm the impact of the 3.0% commission on net proceeds should sales occur.